11/3/2026

speaker
Sandra
Conference Operator

Good day and thank you for standing by. Welcome to the Onward Medical Q3 2026 results webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Alternatively, you may submit your question via the webcast. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sebastien Cros, VP Communications. Please go ahead.

speaker
Sébastien Cros
VP Communications

Thank you, Sandra. Good morning, good afternoon, everyone, and welcome to ONWARD's webcast following the publication of our Q3 2026 results earlier today. Before we get started, let's take a moment to review our disclaimer. The presentation includes forward-looking statements which should be considered with the appropriate level of caution as outlined on the slide. Note that the deck and the recording of the webcast will be available on our website after the call. Today I'm joined by Dave, CEO, Ali, our CFO, and Shari, our Chief Clinical Regulatory and Quality Officer. We'll start with an overview of our third quarter results and key business highlights before opening the floor to questions. You may ask them verbally or submit your questions through the Q&A module on the platform. With that, I'll hand it over to Dave.

speaker
Dave Marver
Chief Executive Officer

Thank you, Seb. Welcome, everyone. I think our first half results call was less than 60 days ago. And so today we're going to deliver a compact and efficient set of remarks to you, starting with the highlights. 88 ArcheX systems were sold or supplied via paid evaluation in Q3. That's 120% year-over-year growth. 31 participants were enrolled and 16 centers activated to date in the EmpowerVP global pivotal study. So we are well positioned to deliver against expectations for a spring 2027 interim data readout. We advanced several of our Arc IM clinical feasibility programs, making important progress in Arc IM mobility, incontinence, and in using Arc IM to address blood pressure instability in Parkinson's disease. You're gonna hear more about that progress from Shari later. And we achieved two and a half million euros in revenue and exited the quarter with more than 73 million euros in cash. Let's go into the details now, starting with ARC-EX and commercial uptake. So as I mentioned, 88 ARC-EX systems were sold or under paid evaluation in Q3. That's 120% year-over-year growth in units. We are now in, so ARC-EX therapy is now offered in more than 150 US clinics and VA facilities, and more than 170 clinics This is really rapid penetration if you consider that full launch in the U.S. has been five quarters and about two quarters in Europe. So we're very pleased with how the marketplace is adopting Arc EX therapy. Reimbursement is an important growth driver now and going forward. So just wanted to walk you through how we're approaching that. We're starting today with customers and customer types where payment already exists. So this includes the VA system, which is the US military healthcare system, and then self-pay. And then earlier this year, we stood up a market access program to enable and support case-by-case submission to other payers. And that now includes Medicare. So in Q3, CMS confirmed DME as our category, and they assigned a miscellaneous HCPCS code to enable case-by-case Thank you for joining us today. I would like to show you actually not Arc IM, but our general pipeline overview. And this really illustrates that Onward is a platform technology company. A lot of companies say that they are. We are making that very much a reality. And I want to focus on the use of Arc IM as a platform. Here in the middle of the slide, you can see five different indications that we're pursuing. And Shari is going to tell you about important progress made in the last quarter in four of those. So using Arc IM to pursue blood pressure instability indication in the spinal cord injury population with the Empower BP clinical study, using Arc IM to restore mobility in the spinal cord injury population in the Iger study, using Arc IM to stabilize blood pressure in the Parkinson's population with funding from the US Department of Defense, and using Arc IM to restore bladder function in the SDI population using funding from the Christopher Reeve Foundation. Take it away, Shari.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API